rosoxacin and Acute-Disease

A total of 112 male patients presenting with acute gonococcal urethritis were admitted to the hospital. The diagnosis was confirmed by smear, culture, oxidase reaction and sugar fermentation tests. The patients were treated with a single 300 mg capsule of rosoxacin. All patients except one showed adequate response to rosoxacin.

Topics: 4-Quinolones; Acute Disease; Adolescent; Adult; Anti-Infective Agents; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Quinolones; Urethritis

Acrosoxacin was given as a single 300 mg oral dose to 105 patients with acute gonorrhoea. Of the 100 patients followed completely there was a 93% cure rate and 33% of men developed postgonococcal urethritis (PGU). This compared with a 97% cure and 30% PGU with 2 megaunits penicillin. The in vitro activity of acrosoxacin in Nottingham against strains of Neisseria gonorrhoeae showed that it was a highly active agent with 90% of strains inhibited by a concentration of 0.03 mg/l.

Topics: 4-Quinolones; Acute Disease; Anti-Bacterial Agents; Female; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Penicillins; Quinolines; Quinolones

61 patients, male and female, with uncomplicated acute gonorrhea were given a single dose of 300 mg rosoxacin (2 capsules). 52 patients only completed clinical and laboratory controls. The drop-out rate for follow-up examinations was 14.8%. 98% of patients were cured. One patient failed to respond to treatment, and six had reinfection seven days later at follow-up control. Three of these were again treated with rosoxacin and cured. Among the side-effects, which were recorded in 24.4% of patients, dizziness was most prevalent (18.1%). Rosoxacin is particularly valuable in gonorrhea, given the single oral dose, the absence of resistance and the high percentage of efficacy.

Topics: 4-Quinolones; Acute Disease; Adolescent; Adult; Anti-Infective Agents; Drug Administration Schedule; Female; Gonorrhea; Humans; Male; Middle Aged; Quinolines; Quinolones

A study of the new anti-bacterial agent, rosoxacin, a quinoline derivative was made in male subjects with uncomplicated acute gonorrhoea using a single oral dose of 200 mg and a single dose of 300 mg. Of the eight patients who received a single dose of 200 mg, post-treatment urethral smears and cultures for N. gonorrhoeae were positive in all and these subjects were considered as treatment failures. In contrast, a single dose of 300 mg was highly effective as all twenty-four who received this dose were cured as judged by negative urethral smears and cultures on the 7th post-treatment day. Of the thirty-eight isolates of M. gonorrhoeae obtained in the study, fifteen (39.5%) were penicillinase-producing, indicating that rosoxacin is effective in treating penicillin-resistant gonorrhoea. Mild to moderate dizziness and/or drowsiness was experienced by four of twenty-nine patients evaluated for safety on the 300 mg single dose, giving an incidence of side-effects of 14%. The symptoms were of brief duration and were self-limiting. A single oral dose of this drug appears to be an ideal treatment for the rapid cure of acute gonorrhoea.

Topics: 4-Quinolones; Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Neisseria gonorrhoeae; Prostatitis; Quinolines; Quinolones